Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15932094 | 0.84 | SMN1; SMN2 (0.47) | SMN1; SMN2RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL15931859 | 0.83 | KMT2A (0.44) | RAB9ADPP4ALDH1A1MEN1KMT2A | |
| SCHEMBL15931904 | 0.83 | THRB (0.51) | SMN1; SMN2RAB9AALDH1A1L3MBTL1THRB | |
| SCHEMBL15932090 | 0.82 | SMN1; SMN2 (0.43) | SMN1; SMN2RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL892449 | 0.81 | RAB9A (0.45) | RAB9ADPP4ALDH1A1MEN1KMT2A | |
| SCHEMBL892883 | 0.79 | HCAR2 (0.57) | SMN1; SMN2THRB | |
| SCHEMBL15931873 | 0.79 | SMN1; SMN2 (0.48) | SMN1; SMN2RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL15932065 | 0.78 | SMN1; SMN2 (0.44) | SMN1; SMN2RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL17320008 | 0.77 | SMN1; SMN2 (0.42) | SMN1; SMN2RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL15511207 | 0.77 | DPP4 (0.37) | SMN1; SMN2RAB9ADPP4ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12178805-B2 | Inhibitors of PDE6Delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders | REMYND N.V. (BE) | 2024-12-31 | — | — | US | disclosed |
| US-11939324-B2 | Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders | REMYND N.V. (BE) | 2024-03-26 | — | — | US | disclosed |
| EP-3621963-B1 | COMPOUNDS FOR THE TREATMENT OF EPILEPSY, NEURODEGENERATIVE DISORDERS AND OTHER CNS DISORDERS | REMYND N V (BE) | 2024-01-24 | — | — | EP | disclosed |
| EP-3621963-B1 | COMPOUNDS FOR THE TREATMENT OF EPILEPSY, NEURODEGENERATIVE DISORDERS AND OTHER CNS DISORDERS | REMYND N V (BE) | 2024-01-24 | — | — | EP | disclosed |
| CN-110650955-B | Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders | 瑞敏德股份有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20230099111-A1 | COMPOUNDS FOR THE TREATMENT OF EPILEPSY, NEURODEGENERATIVE DISORDERS AND OTHER CNS DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-03-30 | — | — | US | disclosed |
| US-11548881-B2 | Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders | REMYND N.V. (BE) | 2023-01-10 | — | — | US | disclosed |
| US-11548881-B2 | Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders | REMYND N.V. (BE) | 2023-01-10 | — | — | US | disclosed |
| US-20200253934-A1 | INHIBITORS OF PDE6DELTA FOR USE IN THE PREVENTION AND/OR TREATMENT OF EPILEPSY AND/OR NEURODEGENERATIVE DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2020-08-13 | — | — | US | disclosed |
| EP-3634407-A1 | INHIBITORS OF PDE6DELTA FOR USE IN THE PREVENTION AND/OR TREATMENT OF EPILEPSY AND/OR NEURODEGENERATIVE DISORDERS | Remynd N.V. (BE) | 2020-04-15 | — | — | EP | disclosed |
| EP-2440550-B1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | UNIV LEUVEN KATH (BE) | 2017-03-15 | — | — | EP | disclosed |
| US-20160324828-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2016-11-10 | — | — | US | disclosed |
| US-9434722-B2 | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2016-09-06 | — | — | US | disclosed |
| CN-102803252-B | Be used for the treatment of indole amides derivative and the related compound thereof of neurodegenerative disorders | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2016-05-25 | — | — | CN | disclosed |
| US-20140066457-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND (BE) | 2014-03-06 | — | — | US | disclosed |
| US-8618138-B2 | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2013-12-31 | — | — | US | disclosed |
| CN-102803252-A | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | UNIV LEUVEN KATH | 2012-11-28 | — | — | CN | disclosed |
| EP-2440550-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2012-04-18 | — | — | EP | disclosed |
| US-20120083475-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2012-04-05 | — | — | US | disclosed |
| WO-2010142801-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083475-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, MAPT, NLN | SMN1; SMN2 80/4885RAB9A 1779/4885DPP4 1744/4885 |
| US-20140066457-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, MAPT, NLN | SMN1; SMN2 81/4885RAB9A 1770/4885DPP4 1787/4885 |
| US-20160324828-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, MAPT, NLN | SMN1; SMN2 81/4885RAB9A 1770/4885DPP4 1787/4885 |
| US-12178805-B2 | Inhibitors of PDE6Delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders | PDE4A, PDE12, PDE2A | SMN1; SMN2 207/4885RAB9A 853/4885DPP4 364/4885 |
| US-20230099111-A1 | COMPOUNDS FOR THE TREATMENT OF EPILEPSY, NEURODEGENERATIVE DISORDERS AND OTHER CNS DISORDERS | MAPT, PSEN1, PSEN2 | SMN1; SMN2 15/4885RAB9A 1661/4885DPP4 2295/4885 |
| US-11548881-B2 | Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders | MAPT, PSEN1, PSEN2 | SMN1; SMN2 15/4885RAB9A 1661/4885DPP4 2295/4885 |
| US-20200253934-A1 | INHIBITORS OF PDE6DELTA FOR USE IN THE PREVENTION AND/OR TREATMENT OF EPILEPSY AND/OR NEURODEGENERATIVE DISORDERS | PDE4A, PDE12, PDE2A | SMN1; SMN2 207/4885RAB9A 853/4885DPP4 364/4885 |
| US-11939324-B2 | Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders | MAPT, PSEN1, PSEN2 | SMN1; SMN2 15/4885RAB9A 1661/4885DPP4 2295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.